Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants

Open access
Yebyo, Henock G, Aschmann, Hélène E, Kaufmann, Marco, Puhan, Milo A · 2019 · American Heart Journal

Abstract

Background: The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta‐analyses that suffer from limitations. Methods: We searched in PubMed for existing systematic reviews and individual open‐label or double‐blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random‐effect pairwise meta‐analysis of all statins as a class and network meta‐analysis for the specific statins on different benefit and harm outcomes. Results: In the pairwise meta‐analyses, statins as a class showed statistically significant risk reductions on non‐fatal MI (risk ratio [RR] 0.62, 95% CI 0.53–0.72), CVD mortality (RR 0.80, 0.71–0.91), all‐cause mortality (RR 0.89, 0.85–0.93), non‐fatal stroke (RR 0.83, 0.75–0.92), unstable angina (RR 0.75, 0.63–0.91), and composite major cardiovascular events (RR 0.74, 0.67–0.81). Statins increased statistically significantly relative and absolute risks of myopathy (RR 1.08, 1.01–1.15; Risk difference [RD] 13, 2–24 per 10,000 person‐years); renal dysfunction (RR 1.12, 1.00–1.26; RD 16, 0–36 per 10,000 person‐years); and hepatic dysfunction (RR 1.16, 1.02–1.31; RD 8, 1–16 per 10,000 person‐years). The drug‐level network meta‐analyses showed that atorvastatin and rosuvastatin were most effective in reducing CVD events while atorvastatin appeared to have the best safety profile. Conclusions: All statins showed statistically significant risk reduction of CVD and all‐cause mortality in primary prevention populations while increasing the risk for some harm risks. However, the benefit‐harm profile differed by statin type. A quantitative assessment of the benefit‐harm balance is thus needed since meta‐analyses alone are insufficient to inform whether statins provide net benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2018.12.007

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 178

Metadata

Authors
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2019-04
Volume
210
Pages
18-28
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2909436318
Cited by
178
References
21
FWCI
6.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. https://app.cochat.ai/papers/10.1016/j.ahj.2018.12.007
The paper
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019). Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal. https://doi.org/10.1016/j.ahj.2018.12.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.